摘要
目的探讨骨髓中蛋白细胞周期激酶抑制剂1C(CDKN1C)的表达在骨髓增生异常综合征(MDS)和继发性急性髓系白血病(AML)患者中检测的临床意义。方法选取125例MDS/AML患者作为研究对象,同时选取20例健康人群作为健康对照组,分析MDS/AML患者骨髓CD34+细胞中CDKN1C mRNA和蛋白表达水平,比较不同CDKN1C的表达水平MDS患者生存率,采用Cox回归分析MDS和AML患者生存率影响因素,并分析治疗方法对不同CDKN1C的表达水平MDS患者生存率的影响。结果 MDS/AML患者骨髓CD34+细胞中CDKN1C mRNA和蛋白表达水平显著高于健康对照组(t=5.324,7.326,P=0.002,0.000),且与BM计数呈正相关(r=2.014,P=0.004);CDKN1C高表达水平组患者的生存率显著低于CDKN1C低表达水平组和CDKN1C中表达水平组(P<0.05);Cox回归分析结果显示高龄、高BM计数、细胞遗传学风险差以及CDKN1C阳性显著影响MDS/AML患者生存率(95%CI=1.10～1.32,1.92～4.40,1.18～2.67,1.03～2.32,P=0.034～0.000);MDS/AML化疗的CDKN1C阳性表达组患者生存率显著低于CDKN1C阴性表达组患者(t=5.314,P=0.002)。结论 MDS/AML患者骨髓中CDKN1C的表达显著增高,CDKN1C高表达显著影响化疗MDS/AML患者的生存率。
Objective To investigate the expression of CDKN1C in bone marrow in myelodysplastic syndromes and clinical significance of the detection of syndrome and secondary acute myeloid leukemia patients. Methods 125 patients with MDS/ AML were selected as the research object,and selected 20 cases of healthy people as healthy control group, and to investigate the mRNA and protein expression in CD34＋ cells in bone marrow the expression of MDS/AML in patients and the survival rate of different expression of CDKN1C,to analyze the factors for survival rate of patients with MDS by Cox regression,and analyze the different treatment methods in patients with MDS/AML. Results The expression levels of CDKNIC mRNA and protein of bone marrow CD34 Jr cells in the patients with MDS/AML were significantly higher than the healthy control group （t=5. 324,7. 326;P=0. 002,0. 000）,and which was positive with BM count （r=-2. 014,P=0. 004） ;the survival rate of CDKNIC high expression levels in patients with MDS/AML was significantly lower than that of the low expression of CDKN1C group and intermediate CDKN1C expression group （P〈0.05）. Cox regression analysis showed that age,high BM count,cytogenetic risk difference and CDKN1C positive significantly affect the survival rate of patients with MDS/AML （95%CI= 1.10-1.32,1.92-4.40,1.18-2.67,1.03-2.32,P=0. 034-0. 000）. MDS/AML chemotherapy in CDKN1C positive group was significantly lower than the survival rate of patients with CDKN1C negative expression group （t=5. 314, P=0. 002）. Conclusion The expression of CDKNIC in bone marrow of patients with MDS/AML was significantly increased, and the high expression of CDKN1CMDS/AML effect of chemotherapy on the survival rate of patients with MDS/ AML.
出处
《现代检验医学杂志》
CAS
2017年第5期36-40,共5页
Journal of Modern Laboratory Medicine
基金
陕西省自然科学基金项目(2013JM4016)
